Emergency departments likely overprescribing opioids for acute pain
1. In this cohort study, majority of the participants did not use all of the opioids prescribed to...
Read MoreJul 28, 2024
1. In this cohort study, majority of the participants did not use all of the opioids prescribed to...
Read MoreJul 26, 2024
1. Tumor response rate at 25 weeks was significantly greater in vimseltinib than placebo. 2. Most...
Read MoreJul 25, 2024
1. Return to baseline function was comparable in tenecteplase and standard-of-care groups. 2. More...
Read MoreJul 23, 2024
1. Co-occurrences could be clustered together into 7 clusters based on the predominant organ...
Read MoreJul 19, 2024
1. In this randomized controlled trial, benralizumab, an anti-interleukin-5 receptor (anti-IL-5R)...
Read MoreJul 16, 2024
1. Median overall survival was 11.5 months in the tisotumab vedotin group and 9.5 months in the...
Read MoreJul 16, 2024
1. In this randomized controlled trial, oral sebetralstat provided faster times to the beginning...
Read MoreJul 14, 2024
1. Patients with bulimia nervosa randomized to receive web-based cognitive behavioural therapy...
Read MoreJul 13, 2024
1. Incentivizing smoking cessation with financial rewards increased the likelihood of cessation...
Read MoreJul 12, 2024
1. Cardiovascular health and infertility are negatively correlated with physical activity, BMI,...
Read MoreJul 11, 2024
1. Periodontitis has a strong association with Type 2 Diabetes and is exacerbated by poor glycemic...
Read MoreJul 9, 2024
1. The complete response rates (pathological and clinical) were similar (~55%) in both groups. 2....
Read MoreJul 7, 2024
1. Unhealthy sleep, as well elevations of liver enzymes and decreased levels of albumin and liver...
Read MoreJul 7, 2024
1. Among US cancer survivors, metformin was associated with a lower risk of cardiometabolic...
Read MoreJul 5, 2024
1. Serum interleukin-1β (IL-1β) and interleukin-6 (IL-6) levels were higher in...
Read MoreJul 4, 2024
1. Femoral neck bone mineral density (FNBMD) alone discriminated 5-year hip fracture risk at least...
Read MoreJul 2, 2024
1. Subcutaneous amivantamab combined with lazertinib was non-inferior to intravenous amivantamab...
Read MoreJul 2, 2024
1. The progression-free survival between the amivantamab–lazertinib group (23.7 months) and the...
Read MoreJun 27, 2024
1. In this randomized controlled trial, CM313, an anti-CD38 monoclonal antibody therapy, was...
Read MoreJun 26, 2024
1. Carriers of the E280A variant of presenilin 1 (PSEN1E280A) who were heterozygous for the...
Read More